Total Payments
$4,486
2024 Payments
$123.98
Companies
4
Transactions
40
Payment Breakdown by Category
Travel$1,927 (42.9%)
Research$1,878 (41.9%)
Food & Beverage$681.17 (15.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $1,927 | 11 | 42.9% |
| Unspecified | $1,878 | 16 | 41.9% |
| Food and Beverage | $681.17 | 13 | 15.2% |
Payments by Type
General
$2,608
24 transactions
Research
$1,878
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,484 | 23 | $0 (2023) |
| ViiV Healthcare Company | $1,170 | 12 | $0 (2017) |
| GlaxoSmithKline, LLC. | $708.86 | 4 | $0 (2017) |
| Gilead Sciences, Inc. | $123.98 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $123.98 | 1 | Gilead Sciences, Inc. ($123.98) |
| 2023 | $860.54 | 8 | Merck Sharp & Dohme LLC ($860.54) |
| 2020 | $784.57 | 8 | Merck Sharp & Dohme Corporation ($784.57) |
| 2017 | $2,717 | 23 | ViiV Healthcare Company ($1,170) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $123.98 | General |
| 02/10/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $49.73 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/10/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $467.97 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $56.23 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/09/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $29.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/08/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $95.17 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/08/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $66.47 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $66.78 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $48.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/15/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | In-kind items and services | $39.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $226.60 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $203.03 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Food and Beverage | Cash or cash equivalent | $39.18 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/13/2020 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | In-kind items and services | $95.57 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/20/2017 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $436.42 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
| 12/20/2017 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $207.91 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
| 12/20/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $184.78 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
| 12/20/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $66.15 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
| 12/20/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $46.39 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
| 12/20/2017 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $35.55 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
| 12/20/2017 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $28.98 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
| 12/20/2017 | ViiV Healthcare Company | — | — | Cash or cash equivalent | $19.53 | Research |
| Study: A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph 3 HIV two year non inferiority compared to standard of care safety tolerability acceptability of long acting injectable regimen | ViiV Healthcare Company | $852.78 | 8 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | GlaxoSmithKline, LLC. | $708.86 | 4 |
| A Phase IIIb, randomized, multicenter, parallel group, non inferiority, open label study evaluating the efficacy, safety, and tolerability of long acting cabotegravir plus long acting rilpivirine administered every 8 weeks or every 4 weeks in HIV 1 infect | ViiV Healthcare Company | $316.85 | 4 |
About Dr. Anne Luetkemeyer, MD
Dr. Anne Luetkemeyer, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1346378940.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anne Luetkemeyer, MD has received a total of $4,486 in payments from pharmaceutical and medical device companies, with $123.98 received in 2024. These payments were reported across 40 transactions from 4 companies. The most common payment nature is "Travel and Lodging" ($1,927).
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location San Francisco, CA
- Active Since 03/02/2007
- Last Updated 01/13/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1346378940
Products in Payments
- MK-3682 (Drug) $838.80
- MK-8591A (Drug) $784.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736